AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $401.96 billion. The enterprise value is $466.08 billion.
Important Dates
The next confirmed earnings date is Friday, October 31, 2025, before market open.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | Oct 15, 2025 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 73.84% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 108.34 and the forward PE ratio is 19.36. AbbVie's PEG ratio is 1.34.
| PE Ratio | 108.34 |
| Forward PE | 19.36 |
| PS Ratio | 6.90 |
| Forward PS | 6.23 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.04 |
| P/OCF Ratio | 20.85 |
| PEG Ratio | 1.34 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 16.60, with an EV/FCF ratio of 25.55.
| EV / Earnings | 125.19 |
| EV / Sales | 7.99 |
| EV / EBITDA | 16.60 |
| EV / EBIT | 23.53 |
| EV / FCF | 25.55 |
Financial Position
The company has a current ratio of 0.74
| Current Ratio | 0.74 |
| Quick Ratio | 0.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.48 |
| Debt / FCF | 3.87 |
| Interest Coverage | 6.92 |
Financial Efficiency
Return on equity (ROE) is 112.85% and return on invested capital (ROIC) is 16.70%.
| Return on Equity (ROE) | 112.85% |
| Return on Assets (ROA) | 8.87% |
| Return on Invested Capital (ROIC) | 16.70% |
| Return on Capital Employed (ROCE) | 20.33% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $67,691 |
| Employee Count | 55,000 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 3.65 |
Taxes
| Income Tax | -741.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.13% in the last 52 weeks. The beta is 0.51, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +21.13% |
| 50-Day Moving Average | 221.44 |
| 200-Day Moving Average | 198.81 |
| Relative Strength Index (RSI) | 51.75 |
| Average Volume (20 Days) | 5,807,719 |
Short Selling Information
The latest short interest is 18.08 million, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 18.08M |
| Short Previous Month | 16.56M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.03% |
| Short Ratio (days to cover) | 2.76 |
Income Statement
In the last 12 months, AbbVie had revenue of $58.33 billion and earned $3.72 billion in profits. Earnings per share was $2.10.
| Revenue | 58.33B |
| Gross Profit | 41.56B |
| Operating Income | 19.80B |
| Pretax Income | 3.03B |
| Net Income | 3.72B |
| EBITDA | 28.07B |
| EBIT | 19.80B |
| Earnings Per Share (EPS) | $2.10 |
Full Income StatementBalance Sheet
The company has $6.47 billion in cash and $70.59 billion in debt, giving a net cash position of -$64.12 billion or -$36.30 per share.
| Cash & Cash Equivalents | 6.47B |
| Total Debt | 70.59B |
| Net Cash | -64.12B |
| Net Cash Per Share | -$36.30 |
| Equity (Book Value) | -138.00M |
| Book Value Per Share | -0.10 |
| Working Capital | -10.51B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $19.28 billion and capital expenditures -$1.04 billion, giving a free cash flow of $18.24 billion.
| Operating Cash Flow | 19.28B |
| Capital Expenditures | -1.04B |
| Free Cash Flow | 18.24B |
| FCF Per Share | $10.32 |
Full Cash Flow StatementMargins
Gross margin is 71.25%, with operating and profit margins of 33.95% and 6.45%.
| Gross Margin | 71.25% |
| Operating Margin | 33.95% |
| Pretax Margin | 5.19% |
| Profit Margin | 6.45% |
| EBITDA Margin | 48.13% |
| EBIT Margin | 33.95% |
| FCF Margin | 31.27% |
Dividends & Yields
This stock pays an annual dividend of $6.56, which amounts to a dividend yield of 2.88%.
| Dividend Per Share | $6.56 |
| Dividend Yield | 2.88% |
| Dividend Growth (YoY) | 5.81% |
| Years of Dividend Growth | 53 |
| Payout Ratio | 312.36% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 2.86% |
| Earnings Yield | 0.93% |
| FCF Yield | 4.54% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $233.74, which is 2.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $233.74 |
| Price Target Difference | 2.73% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 7.54% |
| EPS Growth Forecast (5Y) | 51.60% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.14 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | 6 |
